Tri-Institutional Therapeutics Discovery Institute and LakePharma: A Partnership in Antibody Discovery to Enable Innovative Therapeutics
2021-05-13Category: News
“When we have partnerships with CROs, we are the most successful if we put the collective brain power together in order to find a solution. With LakePharma, we really feel like we are interacting with scientists who are invested in our projects, and we trust their approaches and listen to their suggestions. We have a very high success rate for biologics discovery projects with LakePharma – and we did not give them easy targets; that’s for sure.” -Ivo Lorenz, Ph.D., Vice President of Biologics, Tri-Institutional Therapeutics Discovery Institute, New York, NY |
“LakePharma has a very enthusiastic team. One of my favorite things is that they are flexible with their approaches, are always keen to take on new things, and adapt as the project changes. With LakePharma, there are discussions and adjustments to the approach accordingly. That is important when you are trying to get an immune response going. I respect the science going on there.” -David Andrew, Ph.D., Director of Biologics Lead Identification, Tri-Institutional Therapeutics Discovery Institute, New York, NY |
“We worked on very diverse mechanisms with LakePharma. Because of LakePharma’s broad immunization approaches, we were able to find what we needed for multiple applications. In one example, some antibodies were utilized for CARs, some antibodies were used for radioimmunotherapy, and another set of antibodies was used for ADC approaches. All three modalities were covered with a single discovery campaign run with LakePharma with different antibodies against the same target!” -David Andrew, Ph.D., Director of Biologics Lead Identification -Ivo Lorenz, Ph.D., Vice President of Biologics |
The art of antibody discovery
TDI’s strategic and hopeful biologics portfolio needed diverse panels of mAbs, and LakePharma was just the right partner to deliver both humanized and fully human antibodies! Significantly, in a series of over 10 successful campaigns in three years, the Antibody Center team at LakePharma leveraged their vast experience and expertise to hand select the appropriate animal strains, and to implement their advanced proprietary approaches for immunizations of DNA, protein, and cellular immunogens, generating and screening thousands of hybridomas. In addition, antibodies from various TDI programs were successfully humanized by LakePharma. The outcome: the discovery and optimization of potent, target-specific, fully human or humanized mAbs using proven screening methods, custom antibody characterization assays, and state-of-the-art binding studies.
“The project management at Lake Pharma is excellent; I always feel like I know where the project is through their online client portal.” -David Andrew, Ph.D., Director of Biologics Lead Identification | “We successfully humanized a half dozen antibodies with LakePharma, and we have had a 100% success rate with an efficient approach and fast timeline. ” - Ivo Lorenz, Ph.D., Vice President of Biologics |
Pipeline excitement builds
The partnership between TDI and LakePharma’s Antibody Center teams led to an abundance of novel mAb discoveries that are now in the pipeline for preclinical and clinical studies, awaiting their turn to show their potential in humans in the coming years.
“We have worked with LakePharma on several hybridoma, phage display, and antibody engineering campaigns, including ADC, ADCC, and CAR T programs. These have gone forward to successful applications in vitro and in vivo, and in some cases further to clinical partnerships for TDI and the academic institutions with Fortune 100 pharma or biotech companies.” -Ivo Lorenz, Ph.D., Vice President of Biologics, Tri-Institutional Therapeutics Discovery Institute, New York, NY |
To see an example of the spirit of collaborative scientists from the Tri-Institutional Therapeutics Discovery Institute and LakePharma making great things happen for CAR T development, click on this link: Poster presentation at Antibody Engineering and Therapeutics conference 2019
To learn more about hybridoma technologies, please visit: https://hybridoma.com/